NasdaqGS:ROIVBiotechs
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data
Roivant Sciences (ROIV) is in focus after reporting Phase 2 PHocus data for mosliciguat in pulmonary hypertension associated with interstitial lung disease, showing clinically meaningful, statistically significant improvements in pulmonary vascular resistance and six-minute walk distance.
Roivant Sciences’ latest mosliciguat update comes after a sharp run in the share price, with a 7-day share price return of 16.86% and a 90-day gain of 35.89% contributing to an 86.14% year-to-date share...